...
机译:晚期鳞状细胞肺癌的增量创新与进展:治疗现状与未来影响
Univ Penn Abramson Canc Ctr Dept Thorac Oncol 16 Penn Tower 3400 Civ Ctr Blvd Philadelphia PA;
Eli Lilly &
Co Indianapolis IN 46285 USA;
Univ Colorado Ctr Canc Aurora CO USA;
Rush Univ Med Ctr Chicago IL 60612 USA;
Univ Calif Davis Ctr Comprehens Canc Dept Hematol &
Oncol Sacramento CA 95817 USA;
Univ Colorado Ctr Canc Aurora CO USA;
Carolinas HealthCare Syst Levine Canc Inst Charlotte NC USA;
Cedars Sinai Comprehens Canc Ctr West Hollywood CA USA;
Univ Turin Turin Italy;
Hosp Univ Doce Octubre Madrid Spain;
Leon Berard Canc Ctr Dept Med Oncol Lyon France;
Lung Clin Grosshansdorf Airway Res Ctr North Grosshansdorf Germany;
Emory Univ Winship Canc Inst Dept Hematol &
Med Oncol Atlanta GA 30322 USA;
US Oncol Res Ocala FL USA;
Florida Hosp Inst Canc Orlando FL USA;
Sarah Cannon Res Inst Nashville TN USA;
Stanford Univ Sch Med Palo Alto CA 94304 USA;
Eli Lilly &
Co Indianapolis IN 46285 USA;
Christie Hosp Manchester Lancs England;
NSCLC; Squamous cell lung cancer; Advanced; Therapeutic landscape; Clinically meaningful outcomes;
机译:晚期鳞状细胞肺癌的增量创新与进展:治疗现状与未来影响
机译:高级非小细胞肺癌患者一线治疗的免疫检查点抑制:现状和未来方法
机译:AFATINIB在先进鳞状细胞肺癌中的治疗结果和安全性在基于铂类的双细胞化疗和免疫疗法(空间研究)后进展
机译:机械应变对舌癌Tca8113细胞肺癌A549细胞和鳞癌增殖的影响。
机译:人类非小细胞肺癌亚型,腺癌和鳞状细胞癌以及小鼠肺上皮细胞系的基因表达分析:在肺肿瘤发生中的意义
机译:在接受durvalumab批准之前局部晚期非小细胞肺癌患者同时放化疗的现状和进展
机译:晚期鳞状细胞肺癌的增量创新与进展:治疗现状与未来影响